- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06220669
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants With Relapsing Multiple Sclerosis
The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Poissy, France, 78303
- Centre Hospitalier Intercommunal - Site de Poissy
-
-
-
-
-
Milan, Italy, 20133
- Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta-VIA MANGIAGALLI 3
-
-
-
-
-
Riga, Latvia, LV-1002
- Pauls Stradins Clinical Univeristy Hospital
-
-
-
-
-
Bydgoszcz, Poland, 85-796
- Neurocentrum Bydgoszcz sp. z o.o.
-
Katowice, Poland, 40-686
- NEURO-MEDIC Sp. z o. o.
-
Katowice, Poland, 40-060
- Specjalistyczna Praktyka Lekarska prof. Grzegorz Opala
-
Katowice, Poland, 40-571
- M.A. - LEK A.M. Maciejowscy SC. Centrum Terapii SM
-
Lublin, Poland, 20-064
- Clinirem
-
Poznan, Poland, 61-853
- Niepubliczny Zaklad Opieki Zdrowotnej NEURO-KARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy
-
Warsaw, Poland, 02-677
- ETG Neuroscience - PPDS
-
Zabrze, Poland, 41-800
- IBISMED Wielospecjalistyczne Centrum Medyczne
-
Żory, Poland, 44-240
- ProNeuro Centrum Medyczne
-
-
-
-
-
Bratislava, Slovakia, 826 06
- Nemocnica Ruzinov
-
-
-
-
-
Nottingham, United Kingdom, NG7 2UH
- Queen's Medical Centre
-
-
-
-
Florida
-
Gulf Breeze, Florida, United States, 32561
- Panhandle Research and Medical Clinic
-
Winter Park, Florida, United States, 32789
- Conquest Research LLC - Winter Park - ClinEdge - PPDS
-
-
Illinois
-
Northbrook, Illinois, United States, 60062
- Consultants in Neurology
-
-
Missouri
-
Ozark, Missouri, United States, 65721-5315
- Sharlin Health and Neurology
-
-
South Carolina
-
Greer, South Carolina, United States, 29605
- Premier Neurology
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37922
- Hope Neurology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
Participants must meet criteria for relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis based on the 2017 revision of the McDonald diagnostic criteria (Thompson et al. 2018) with a relapsing course (RMS) activity according to Klineova and Lublin 2018.
-
Participants must have 1 of these:
- at least 1 documented relapse within the previous year
- at least 2 documented relapses within the previous 2 years, or
- at least 1 active GdE brain lesion on an MRI scan in the past 180 days prior to screening.
-
Have an Expanded Disability Status Scale (EDSS) score of less than or equal to (≤) 5.5 at screening and randomization.
Exclusion Criteria:
-
Have had a diagnosis of:
- primary progressive multiple sclerosis (MS) according to the 2017 revision of McDonald diagnostic criteria (Thompson et al. 2018), or
- nonactive secondary progressive MS ( Klineova and Lublin 2018).
-
Meet criteria for neuromyelitis optica spectrum disorder (Wingerchuk and Lucchinetti 2022).
-
Have a history of clinically significant central nervous system (CNS) disease.
-
Have had a confirmed relapse with systemic corticosteroid administration <30 days prior to randomization.
-
Have more than 20 active GdE brain lesions on screening MRI scan.
-
Have received any of these medications or treatments.
-
Have a current or recent acute, active infection.
-
Have current serious or unstable illnesses.
-
Have any other clinically important abnormality at screening or baseline.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: LY3541860 Phase 2a Dose Level 1
LY3541860 will be given intravenously (IV) |
Administered IV |
|
Experimental: LY3541860 Phase 2a Dose Level 2
LY3541860 will be given IV. |
Administered IV |
|
Placebo Comparator: Placebo Phase 2a
Placebo will be given IV. |
Administered IV |
|
Experimental: LY3541860 Phase 2b Dose Level 3
LY3541860 will be given IV. |
Administered IV |
|
Experimental: LY3541860 Phase 2b Dose Level 4
LY3541860 will be given IV. |
Administered IV |
|
Placebo Comparator: Placebo Phase 2b
Placebo will be given IV. |
Administered IV |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions
Time Frame: 12 Weeks
|
Cumulative number will be measured by magnetic resonance imaging (MRI) scans. |
12 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cumulative Number of Total Number of T1 GdE Lesions
Time Frame: 12 Weeks
|
Cumulative number will be measured by MRI scans. |
12 Weeks
|
|
Cumulative Number of New and/or Enlarging T2 Lesions
Time Frame: 12 Weeks
|
Cumulative number will be measured by MRI scans. |
12 Weeks
|
|
Pharmacokinetics (PK): Plasma Trough Concentrations of LY3541860
Time Frame: Baseline Through Week 12
|
Plasma trough concentrations of LY3541860 was measured. |
Baseline Through Week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18548
- J3K-MC-KIAB (Other Identifier: Eli Lilly and Company)
- 2023-503289-22-00 (Other Identifier: EU Trial Number)
- 2023 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD Sharing Time Frame
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD Sharing Access Criteria
research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.